Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Targeting the Lipid Metabolism Proteins FASN and GPAM in Alveolar Type II Cells Decreases Lung Metastasis

  • Liu, Xiao-Zheng
  • Panina, Yulia
  • Cai, Weigang
  • Fernández-García, Juan
  • Peng-Winkler, Yiming
  • Mao, Jiadong
  • Dahlhaus, Alina
  • Zhou, Hui-Chao
  • Liu, Ming
  • Planque, Mélanie
  • Ceuppens, Johannes
  • Igelmann, Sebastian
  • Spotbeen, Xander
  • Idkowiak, Jakub
  • Dehairs, Jonas
  • Theile, Janine
  • Axarlis, Konstantinos
  • Borremans, Kristien
  • Van Cauwenberge, Josephine
  • Ghanate, Avinash
  • Tarragó-Celada, Josep
  • Suárez-Bonnet, Alejandro
  • Mitter, Richard
  • Wu, Vincen
  • Inglese, Paolo
  • McKenzie, James S.
  • Steven, Rory T.
  • Dexter, Alex
  • Yan, Bin
  • Vorng, Jean-Luc
  • Takáts, Zoltán
  • Bunch, Josephine
  • Gilmore, Ian S.
  • Carmeliet, Peter
  • Desmedt, Christine
  • Malanchi, Ilaria
  • Swinnen, Johannes V.
  • Altea-Manzano, Patricia
  • Lê Cao, Kim-Anh
  • Meiser, Johannes
  • Yuneva, Mariia
  • Fendt, Sarah-Maria
Cancer cells that seed in the lung require lipids often produced by alveolar type II (AT2) cells. However, whether overt metastases depend on AT2 cell-derived lipids and whether AT2 cells can be targeted to reduce metastasis growth remains unknown. We discovered that breast cancer-derived lung metastases stimulate the proliferation of AT2 cells in their vicinity and reprogram them into lipid feeder cells in mice and patients using spatial analysis. Mechanistically, the metastasis secretome activates the transcription factor sterol regulatory element-binding transcription factor 1 (SREBP-1) in AT2 cells, enhancing the expression of key de novo lipid synthesis genes, including fatty acid synthase (FASN) and glycerol-3-phosphate acyltransferase 1 (GPAM). Deleting Fasn selectively in AT2 cells or targeting FASN and GPAM systemically significantly impairs lung metastasis growth in mice. In summary, we discovered that overt metastases reprogram AT2 cells and that targeting the lipid metabolism of AT2 cells impairs metastasis growth., X.-Z. Liu was an EMBO postdoctoral fellow (ALTF 401-2022) and has received funding from FWO (1231025N) and Gilead Sciences Research Scholars Program in Solid Tumors and Research Foundation as well as the Beug Foundation. J. Fernández-García is a previous recipient of Research Foundation – Flanders (FWO) junior/senior postdoctoral fellowships. P. Altea-Manzano was supported by a Marie Sklodowska-Curie Actions individual fellowship (MSCA-IF-2018-839896) and has received funding from European Union (ERC-StG-101116912) and Beug Foundation. Y. Peng-Winkler has received a Walter Benjamin Fellowship from the German Research Foundation (DFG 521676159). J. Mao and K.-A. Lê Cao were supported by the Australian National Health and Medical Research Council (NHMRC) Investigator Grant (GNT2025648). J. Meiser received funding from the European Union (ERC-CoG-101124557) and Luxembourgish research Fund (FNR-CORE C21/BM/15718879). M. Liu has received a fellowship from the Chinese Research Council (CSC). S. Igelmann received funding from EMBO postdoctoral fellow (ALTF 13-2022) and from Research Foundation – Flanders (FWO) junior postdoctoral fellowship (1266225N). J. Van Cauwenberge and K. Borremans were funded by the fund Nadine de Beauffort. The UPTIDER program is supported by a grant from from the Klinische Onderzoeks- en Opleidingsraad (KOOR) of University Hospitals Leuven (Uitzonderlijke Financiering 2020), by C1 of KU Leuven (C14/21/114), by the Belgian Cancer Foundation (grant number: C/2022/2046), by the Research Foundation Flanders (FWO, grant number: G082524N) and by the Breast Cancer Research Foundation (BCRF, grant number: BCRF-24-212). M. Yuneva, Z. Takáts and J. Bunch acknowledge funding from the CRUK Grand Challenge Award 2015 C57633/A25043. M. Yuneva acknowledges funding from the Francis Crick Institute, which receives its core funding from Cancer Research UK (FC001223), the UK Medical Research Council (FC001223), and the Wellcome Trust (FC001223, FC0010060). S.-M. Fendt acknowledges funding from FWO Projects, Fonds Baillet Latour, Francqui Stichting, Foundation ARC, KU Leuven C1, Small Equipment and Methusalem programs (METH/26/009), Stichting tegen Kanker (2022-173 and 2022-034), and Wereld Kanker Onderzoek Fonds (WKOF), as part of the World Cancer Research Fund International grant program (IIG_FULL_2023_001) and the Interuniversity BOF (iBOF) program., Peer reviewed